Adagio Therapeutics Inc (NASDAQ:ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19. The company plans to seek U.S. Emergency Use Authorization.
"COVID-19 continues to pose significant challenges globally as waning immunity combined with the emergence of resistant variants has led to ongoing waves of disease," said David Hering, interim CEO and CIO of Adagio.
